文献速递慢性肾脏病肾血管病与高血压

房颤患者不同肾小球滤过率下直接口服抗凝药的风险与获益

Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-07-12

本研究在Geisinger健康系统中构建倾向评分匹配队列,比较3206例使用直接口服抗凝药(DOAC)与3206例使用华法林的房颤患者,按eGFR≥60和<60 ml/min per 1.73 m2分层。结果显示eGFR<60者使用DOAC出血风险略高于华法林(HR 1.23,95%CI 1.02-1.48),但缺血性卒中风险无差异。

要点

  • eGFR<60的房颤患者使用DOAC较华法林出血风险略高。
  • eGFR≥60者DOAC与华法林出血风险无显著差异。
  • 两分层中DOAC与华法林的缺血性卒中风险均无差异。

核心结论

  • eGFR<60 ml/min per 1.73 m2的房颤患者使用DOAC较华法林出血风险略高,但预防缺血性卒中的获益相似。

研究设计与样本

  • 倾向评分匹配队列研究,纳入2010年10月至2017年2月Geisinger健康系统房颤患者,DOAC组3206例,华法林组3206例。

主要发现

  • 平均年龄72(12)岁,女性47%,平均eGFR 69(21)ml/min per 1.73 m2,随访7391人年,出血事件1181例,缺血性卒中466例。
  • eGFR≥60者DOAC vs 华法林出血HR 1.01(95%CI 0.88-1.17),eGFR<60者HR 1.23(95%CI 1.02-1.48),交互P=0.10。
  • eGFR≥60者缺血性卒中HR 0.94(95%CI 0.74-1.18),eGFR<60者HR 1.02(95%CI 0.76-1.37),交互P=0.70。
  • 单个药物分析结果相似。

临床怎么用

  • eGFR<60的房颤患者选用DOAC时需更关注出血风险,但卒中预防获益与华法林相当。

局限性

  • 原文未明确列出局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: All randomized trials of direct oral anticoagulants in atrial fibrillation excluded patients with severe kidney disease. The safety and effectiveness of direct oral anticoagulants across the range of eGFR in real-world settings is unknown. Our objective is to quantify the risk of bleeding and benefit of ischemic stroke prevention for direct oral anticoagulants compared with warfarin in patients with atrial fibrillation with and without CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We created a propensity score-matched cohort of 3206 patients with atrial fibrillation and direct oral anticoagulant use and 3206 patients with atrial fibrillation using warfarin from October of 2010 to February of 2017 in an electronic health record (Geisinger Health System). The risks of bleeding and ischemic stroke were compared between direct oral anticoagulant and warfarin users using Cox proportional hazards regression, stratified by eGFR (≥60 and <60 ml/min per 1.73 m2). RESULTS: The mean (SD) age of the 6412 participants was 72 (12) years, 47% were women, and average eGFR was 69 (21) ml/min per 1.73 m2. There were 1181 bleeding events and 466 ischemic strokes over 7391 person-years of follow-up. Compared with warfarin use, the hazard ratios (HRs) (95% confidence interval [95% CI]) of bleeding associated with direct oral anticoagulant use were 1.01 (0.88 to 1.17) and 1.23 (1.02 to 1.48) for those with eGFR≥60 and eGFR<60 ml/min per 1.73 m2, respectively (P-interaction=0.10). There was no difference between direct oral anticoagulant and warfarin users in the risk of ischemic stroke: HRs (95% CI) of 0.94 (0.74 to 1.18) and 1.02 (0.76 to 1.37) for those with eGFR≥60 and eGFR<60 ml/min per 1.73 m2, respectively (P-interaction=0.70). Similar findings were observed with individual drugs. CONCLUSIONS: In a large health care system, patients with eGFR<60 ml/min per 1.73 m2 who took direct oral anticoagulants for atrial fibrillation had slightly higher risk of bleeding compared with those on warfarin, but similar benefits from prevention of ischemic stroke.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Shin JI, Secora A, Alexander GC, et al. Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation. Clin J Am Soc Nephrol. 2018. PMID: 30002224. doi:10.2215/CJN.13811217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。